Major histocompatibility complex (MHC) class I ligands are mainly produced by the proteasome. Herein, we show that the processing of antigens is regulated by two distinct pathways, one requiring PA28 and the other hsp90. Both hsp90 and PA28 enhanced the antigen processing of ovalbumin (OVA). Geldanamycin, an inhibitor of hsp90, almost completely suppressed OVA antigen presentation in PA28α−/−/β−/− lipopolysaccharide blasts, but not in wild-type cells, indicating that hsp90 compensates for the loss of PA28 and is essential in the PA28-independent pathway. In contrast, treatment of cells with interferon (IFN)-γ, which induces PA28 expression, abrogated the requirement of hsp90, suggesting that IFN-γ enhances the PA28-dependent pathway, whereas it diminishes hsp90-dependent pathway. Importantly, IFN-γ did not induce MHC class I expressions in PA28-deficient cells, indicating a prominent role for PA28 in IFN-γ–stimulated peptide supply. Thus, these two pathways operate either redundantly or specifically, depending on antigen species and cell type.
Skip Nav Destination
Article navigation
15 July 2002
Article|
July 08 2002
Two Distinct Pathways Mediated by PA28 and hsp90 in Major Histocompatibility Complex Class I Antigen Processing
Taketoshi Yamano,
Taketoshi Yamano
1Department of Molecular Medicine, Division of Immunology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
Search for other works by this author on:
Shigeo Murata,
Shigeo Murata
2Department of Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, and CREST, Japan Science and Technology Corporation, Tokyo 113-8613, Japan
Search for other works by this author on:
Naoki Shimbara,
Naoki Shimbara
3UpScience, Incorporated, Yokohama 244-8588, Japan
Search for other works by this author on:
Noriaki Tanaka,
Noriaki Tanaka
4First Department of Surgery, Okayama University Medical School, Okayama 700, Japan
Search for other works by this author on:
Tomoki Chiba,
Tomoki Chiba
2Department of Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, and CREST, Japan Science and Technology Corporation, Tokyo 113-8613, Japan
Search for other works by this author on:
Keiji Tanaka,
Keiji Tanaka
2Department of Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, and CREST, Japan Science and Technology Corporation, Tokyo 113-8613, Japan
Search for other works by this author on:
Katsuyuki Yui,
Katsuyuki Yui
1Department of Molecular Medicine, Division of Immunology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
Search for other works by this author on:
Heiichiro Udono
Heiichiro Udono
1Department of Molecular Medicine, Division of Immunology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
Search for other works by this author on:
Taketoshi Yamano
1Department of Molecular Medicine, Division of Immunology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
Shigeo Murata
2Department of Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, and CREST, Japan Science and Technology Corporation, Tokyo 113-8613, Japan
Naoki Shimbara
3UpScience, Incorporated, Yokohama 244-8588, Japan
Noriaki Tanaka
4First Department of Surgery, Okayama University Medical School, Okayama 700, Japan
Tomoki Chiba
2Department of Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, and CREST, Japan Science and Technology Corporation, Tokyo 113-8613, Japan
Keiji Tanaka
2Department of Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, and CREST, Japan Science and Technology Corporation, Tokyo 113-8613, Japan
Katsuyuki Yui
1Department of Molecular Medicine, Division of Immunology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
Heiichiro Udono
1Department of Molecular Medicine, Division of Immunology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
Address correspondence to Heiichiro Udono, Department of Molecular Medicine, Division of Immunology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan. Phone: 81-95-849-7071; Fax: 81-95-849-7073; E-mail: [email protected]
*
Abbreviations used in this paper: BFA, brefeldin A; ER, endoplasmic reticulum; GA, geldanamycin; HA, herbimycin A; LC, lactacystin; MEF, murine embryonic fibroblast; TAP, transporter associated with antigen processing; TRP, tyrosinase-related protein.
Received:
November 16 2001
Revision Received:
May 10 2002
Accepted:
June 03 2002
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2002
J Exp Med (2002) 196 (2): 185–196.
Article history
Received:
November 16 2001
Revision Received:
May 10 2002
Accepted:
June 03 2002
Citation
Taketoshi Yamano, Shigeo Murata, Naoki Shimbara, Noriaki Tanaka, Tomoki Chiba, Keiji Tanaka, Katsuyuki Yui, Heiichiro Udono; Two Distinct Pathways Mediated by PA28 and hsp90 in Major Histocompatibility Complex Class I Antigen Processing . J Exp Med 15 July 2002; 196 (2): 185–196. doi: https://doi.org/10.1084/jem.20011922
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement